Ειδήσεις: MAZE THERAPEUTICS | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

28/03 07:48 defenseworld.net

HC Wainwright Issues Optimistic Outlook for MAZE Earnings

Maze Therapeutics HC Wainwright earnings forecast buy rating price target Q1 2026

27/03 09:38 defenseworld.net

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Therapeutics MZE829 APOL1 kidney disease Phase II proteinuria HORIZON study

27/03 07:42 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Shares Up 5.5% After Better-Than-Expected Earnings

Maze Therapeutics earnings beat stock price Phase 2 HORIZON MZE829 uACR reduction

26/03 09:36 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Receives Buy Rating from BTIG Research

Maze Therapeutics BTIG Research buy rating price target NASDAQ analyst upgrade

26/03 09:36 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright

Maze Therapeutics HC Wainwright price target buy rating Nasdaq biotech

18/03 08:08 defenseworld.net

Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $54.63

Maze Therapeutics NASDAQ analysts price target buy rating biotech

17/03 07:46 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade

Maze Therapeutics NASDAQ stock price analyst upgrade 52‑week high Wedbush

17/03 07:46 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade

Maze Therapeutics NASDAQ stock price analyst upgrade 52‑week high Wedbush

Loading...